Business Combinations (Narrative) (Details) - USD ($)	3 Months Ended		12 Months Ended
	Apr. 05, 2020	Mar. 31, 2019	Dec. 29, 2019	Jan. 03, 2016	Dec. 30, 2018
Business Acquisition [Line Items]
Number of Years in Measurement Period from Acquisition Date to Change Underlying Assumptions	1 year
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High	$ 57,100,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value	$ 22,777,000	$ 34,349,000	$ 35,481,000		$ 69,661,000
Business Combination, Contingent Consideration Arrangements, Maximum Period	2 years 9 months 18 days
Business Combination, Contingent Consideration Arrangements, Weighted Average Period	1 year
Total transaction costs	$ 12,400,000	1,800,000
Business Combination, Contingent Consideration Arrangements, Description	Contingent consideration is measured at fair value at the acquisition date, based on the probability that revenue thresholds or product development milestones will be achieved during the earnout period, with changes in the fair value after the acquisition date affecting earnings to the extent it is to be settled in cash.
Goodwill	$ 3,051,694,000		3,111,227,000
Business Combination, Contingent Consideration, Liability, Current	20,500,000		20,800,000
Business Combination, Contingent Consideration, Liability, Noncurrent	2,300,000		14,700,000
Foreign Currency Transaction Gain (Loss), before Tax	(7,900,000)	(100,000)
Interest Expense	13,665,000	15,850,000
Business Combination, Contingent Consideration, Liability	22,800,000		35,500,000
Shandong Meizheng [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments			(2,961,000)
Business Combination, Consideration Transferred			164,399,000
Cash Acquired			2,108,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets			15,160,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment			6,278,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets			32,000
Cash paid to the shareholders			145,000,000
Business Combination, Consideration Transferred, Liabilities Incurred			6,446,000
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value			12,100,000
Goodwill	79,175,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt			10,991,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net			$ 164,399,000
Compensation Expense, Excluding Cost of Good and Service Sold	12,300,000
Fiscal Year 2019 Acquisitions [Member]
Business Acquisition [Line Items]
Goodwill, Purchase Accounting Adjustments	(1,600,000)
Acquired Finite-lived Intangible Assets, Weighted Average Useful Life			11 years
Business Combination, Increase (Decrease) in Deferred Tax Liabilities	(300,000)
Business Combination, Increase (Decrease) in Intangible Assets	(1,900,000)
Cisbio Bioassays SAS [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments			$ (138,000)
Business Combination, Consideration Transferred			207,391,000
Cash Acquired			12,542,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets			43,554,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment			4,835,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets			100,000
Cash paid to the shareholders			219,795,000
Business Combination, Consideration Transferred, Liabilities Incurred			0
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value			0
Goodwill	73,061,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt			12,553,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net			207,391,000
2019 Acquisitions (excluding Cisbio) [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost Of Acquired Entity, Working Capital Adjustments			(302,000)
Business Combination, Consideration Transferred			45,282,000
Cash Acquired			1,334,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets			4,042,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment			727,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets			481,000
Cash paid to the shareholders			45,042,000
Business Combination, Consideration Transferred, Liabilities Incurred			638,000
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value			634,000
Goodwill	17,005,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt			3,295,000
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net			45,282,000
Vanadis Diagnostics AB [Member]
Business Acquisition [Line Items]
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High				$ 93,000,000.0
Business Acquisition, Cost of Acquired Entity, Liabilities Incurred, Contingent Consideration at Fair Value	18,500,000			$ 56,900,000
Tulip Diagnostics Private Limited [Member]
Business Acquisition [Line Items]
Compensation Expense, Excluding Cost of Good and Service Sold		$ 500,000
Diagnostics [Member]
Business Acquisition [Line Items]
Goodwill	1,582,380,000		1,612,407,000
Discovery & Analytical Solutions [Member]
Business Acquisition [Line Items]
Goodwill	1,469,314,000		1,498,820,000
Core Technology [Member] | Shandong Meizheng [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	36,600,000
Core Technology [Member] | Cisbio Bioassays SAS [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	89,000,000
Core Technology [Member] | 2019 Acquisitions (excluding Cisbio) [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			27,667,000
Customer Relationships [Member] | Shandong Meizheng [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles	$ 55,800,000
Customer Relationships [Member] | Cisbio Bioassays SAS [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			39,000,000
Customer Relationships [Member] | 2019 Acquisitions (excluding Cisbio) [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			6,700,000
Trade Names [Member] | Shandong Meizheng [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			4,900,000
Trade Names [Member] | Cisbio Bioassays SAS [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			5,000,000
Trade Names [Member] | 2019 Acquisitions (excluding Cisbio) [Member]
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles			1,310,000
United States of America, Dollars | Shandong Meizheng [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments			166,500,000
United States of America, Dollars | Fiscal Year 2019 Acquisitions [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments			433,100,000
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High			31,800,000
United States of America, Dollars | Cisbio Bioassays SAS [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments			219,900,000
United States of America, Dollars | 2019 Acquisitions (excluding Cisbio) [Member]
Business Acquisition [Line Items]
Business Acquisition, Cost of Acquired Entity, Cash Paid Including Working Capital And Other Adjustments			$ 46,600,000